ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 358

Six Months of an Attenuated Cobra Regimen (‘COBRA-light’) Is Clinically Noninferior to the Original Cobra Regimen: An Open-Label Randomized Trial in Early Rheumatoid Arthritis

Debby den Uyl1, Marieke M. ter Wee1, Maarten Boers2, Alexandre Voskuyl3, P.J.S.M. Kerstens4, Mike T. Nurmohamed5, Hennie G. Raterman1, Dirkjan van Schaardenburg5, N. van Dillen4, B.a.C Dijkmans1 and W.F. Lems1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 3Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, Reade | Jan van Breemen Research Institute, Amsterdam, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: combination therapies, randomized trials and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Early, intensive treatment of rheumatoid arthritis (RA) with combination therapy (COBRA therapy) considerably lowers disease activity and suppresses radiological progression. Although proven to be very effective, uptake of COBRA therapy among rheumatologists has been suboptimal, for reasons including fear of possible side-effects. A modified schedule of the COBRA therapy with a lower dose of prednisone (‘COBRA-light’), might be equally effective and lessen concerns about side-effects. The purpose of this study was to investigate whether COBRA-light therapy is non-inferior to COBRA-therapy in patients with early, active RA. Trial duration: one year.

Methods:

164 patients with early, active RA were randomised to either COBRA therapy (MTX 7.5 mg/week, SSZ 2 g/day and prednisone 60 mg/d, tapered to 7.5 mg/day) (n=81) or COBRA-light therapy (MTX 25 mg/week and 30 mg prednisone, tapered to 7.5 mg/day) (n=83). Primary treatment goal was minimal disease activity, defined as DAS44 < 1.6. After 3 months treatment, MTX dose could be increased up to 25mg/week, when DAS44 remained above 1.6. A difference in change of DAS44 > 0.5 between the groups after 6 months was considered clinically relevant, and set as the boundary of non-inferiority. Patients, physicians and assessors were aware of treatment allocation as this trial is an open label trial.

Results:

At baseline, patients had moderately active disease: COBRA, mean (SD) DAS44 4.13 (0.81); COBRA-light, 3.95 (0.90). Two patients (COBRA-light arm) did not initiate treatment and two patients dropped-out of the study due to adverse events (myocardial infarction in COBRA-arm and manic episode in COBRA-light arm). At 6 months DAS44 had significantly decreased in both groups: COBRA, –2.50 (1.21); COBRA-light, –2.18 (1.10) (Table). The difference between the groups in DAS44 change was 0.32 (95% CI: –0.03;0.68; p=0.08), i.e. within the noninferiority boundary. Minimal disease activity (DAS44<1.6) was reached in almost half of patients in both groups (49% and 41% in COBRA and COBRA-light respectively). There were no significant differences between the treatment groups with respect to other measurements of disease activity including the EULAR and ACR response criteria and the HAQ-score.

Conclusion:

Results at 6 months suggest that COBRA-light therapy is non-inferior to standard COBRA therapy: both strategies effectively lower disease activity in early, active RA patients. The clinical and radiological effects at one year are pending.

 

Table 1 Outcome week 26

 

 

COBRA (n=81)

COBRA-light (n=81)

P

D DAS44*

-2.50 (1.21)

-2.18 (1.10)

0.08

Absolute DAS44

1.63 (0.96)

1.77 (1.14)

NS

Minimal disease activity

(DAS44<1.6)

49%

41%

NS

D HAQ

-0.8 (0.6)

-0.8 (0.7)

NS

D Tender joints

-14 (11)

-13 (11)

NS

D Swollen joints

-11 (6)

-10 (6)

NS

D ESR, mm/h

-21.5 (-37;-8)

-13.5 (-34;-4)

0.09

D CRP mg/L

-9.5 (-25;-1)

-8.5 (-29;-1)

NS

D Patient’s global assessment disease activity, (0-100)

-34 (-59;-7)

-41 (-65;-17)

NS

D Physician’s global assessment disease activity, (0-100)

-36 (-59;-9)

-31 (-54;-10)

NS

ACR 20 response

72%

72%

NS

ACR 50 response

56%

62%

NS

ACR 70 response

37%

49%

NS

EULAR good response

75%

65%

NS

EULAR non-response

6%

11%

NS

ACR/EULAR remission (Boolean)

15%

24%

NS

Intra-articular injections, n (%)

0%

4%

NS

* D: delta, difference between 0 and 26 weeks

Data are presented as mean (±SD) or median (interquartile range). Differences between groups were tested with independent T-test, Mann-Whitney U test or Chi square test. A p<0.05 was considered statistically significant.

 


Disclosure:

D. den Uyl,
None;

M. M. ter Wee,
None;

M. Boers,
None;

A. Voskuyl,
None;

P. J. S. M. Kerstens,
None;

M. T. Nurmohamed,
None;

H. G. Raterman,
None;

D. van Schaardenburg,
None;

N. van Dillen,
None;

B. A. C. Dijkmans,
None;

W. F. Lems,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/six-months-of-an-attenuated-cobra-regimen-cobra-light-is-clinically-noninferior-to-the-original-cobra-regimen-an-open-label-randomized-trial-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology